Clinical Trials Logo

Overactive Bladder clinical trials

View clinical trials related to Overactive Bladder.

Filter by:

NCT ID: NCT01901120 Completed - Overactive Bladder Clinical Trials

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Start date: October 2012
Phase: N/A
Study type: Observational

This study is to evaluate the safety and efficacy of long-term use of Betanis (generic name: mirabegron), and to determine the adherence to treatment with mirabegron.

NCT ID: NCT01898624 Completed - Overactive Bladder Clinical Trials

Specified Drug Use-results Survey of Betanis Tablets

Start date: December 4, 2012
Phase: N/A
Study type: Observational

To investigate the effects of mirabegron on the symptoms of glaucoma in overactive bladder (OAB) patients with coexisting glaucoma.

NCT ID: NCT01870037 Completed - Overactive Bladder Clinical Trials

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

OAB
Start date: January 2013
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety of a single treatment of hMaxi-K compared to placebo (PBS-20% sucrose) administered by direct bladder wall injections. Two dose levels (16000 µg and 24000 µg; 20 or 30 bladder wall injections, respectively) in females with moderate Overactive Bladder/Detrusor overactivity (OAB/DO) of ≥6 months duration will be evaluated. In each dose level, 6 participants will receive hMaxi-K and 3 will receive placebo.

NCT ID: NCT01868516 Completed - Overactive Bladder Clinical Trials

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

Start date: May 2013
Phase: Phase 2
Study type: Interventional

Overactive bladder (OAB) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking). The purpose of this study is to test whether dexmecamylamine is safe and effective compared to placebo for the treatment of symptoms of OAB.

NCT ID: NCT01833663 Completed - Overactive Bladder Clinical Trials

Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women

OAB
Start date: October 2011
Phase: Phase 4
Study type: Interventional

This study is a multi-site, randomized, opened and parallel-controlled clinical study. The patients up to the inclusion criteria are randomly treated with Solifenacin Succinate Tablets (5mg/d) or Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks. Before the dosing and at Week 4, 8 and 12 of the dosing, various examinations are made, and various indices are evaluated.

NCT ID: NCT01824420 Completed - Overactive Bladder Clinical Trials

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

Start date: March 2013
Phase: Phase 4
Study type: Interventional

To investigate if oxybutynin ER adding on antimuscarinics is more effective than mono-antimuscarinic treatment for patients with refractory OAB

NCT ID: NCT01768910 Completed - Multiple Sclerosis Clinical Trials

Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction

Start date: December 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to provide profound insight into the supraspinal neuronal mechanisms and networks responsible for lower urinary tract (LUT) control and to verify, amend or adjust neuronal circuitry models established from findings in healthy subjects in the context of neurogenic and non-neurogenic LUT dysfunction.

NCT ID: NCT01767519 Completed - Clinical trials for Urinary Incontinence

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

Start date: March 1, 2013
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of BOTOX® or Solifenacin in patients with overactive bladder (OAB) and urinary incontinence.

NCT ID: NCT01747577 Completed - Overactive Bladder Clinical Trials

Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)

POST-TURP
Start date: December 4, 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to demonstrate superiority of the solifenacin succinate (treatment) over the placebo (control) based on the change from the baseline in the mean number of urgency episodes per 24 hours after 2 weeks.

NCT ID: NCT01745094 Completed - Overactive Bladder Clinical Trials

A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

Start date: October 1, 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of mirabegron as add-on therapy in patients with OAB treated with solifenacin.